Leveraging NCI SBIR & STTR Opportunities for Early-Stage and Venture-Backed Companies

We are excited to be able to partner again with the National Cancer Institute to bring BayBio members a webinar on SBIR and STTR opportunities. Registration is required to participate in the webinar but comes at no charge.

On Tuesday, November 19, the Council of State Bioscience Associations (CSBA), of which BayBio is a member, is collaborating with the National Cancer Institute Small Business Development Center to provide members an exclusive chance to learn more about the funding opportunities and resources offered by the NCI Small Business Innovation Research (SBIR) Programs. The NCI SBIR Development Center can help progress the development of your novel technologies and therapeutics for the advancement of cancer research.

The webinar session will be led by Michael Weingarten, Director of the NCI SBIR Development Center and Andrew Kurtz, PhD, Program Director & Team Leader, and will highlight initiatives designed to help early-stage companies advance their promising innovations from the lab to the marketplace. Please feel free to share this invitation with your network.

NCI SBIR Webinar for Council of State BIO Association Members
November 19, 2013
12:00 p.m. – 1:45 p.m. (EST)

This is an important event for state BIO members to participate in and learn more about the NCI SBIR & STTR Programs. The following topics will be covered:

  • Overview of the NCI SBIR & STTR Programs.
  • Information about NCI’s grant funding opportunities, contract funding opportunities, and details on the Phase IIB Bridge Award.
  • Recent policy changes that expand program eligibility to venture capital backed companies.
  • Practical strategies and tips for developing successful and competitive proposals, proper stage of development, and other factors that NCI is looking for when reviewing applications.

For a complete list of NCI SBIR & STTR funding opportunities, please visit http://sbir.cancer.gov/funding/receipt_dates.asp.

There are many benefits to applying for NCI SBIR & STTR funding opportunities, such as:

  • SBIR & STTR funding can be a leveraging tool to help attract additional funding from other third-party investors.
  • Awards are not loans; no repayment is required.
  • SBIR & STTR funding is non-dilutive capital (i.e., an award does not impact the company’s stock or shares in any way). Intellectual property rights to technologies developed under these programs are retained by the small business concern.
  • SBIR & STTR awards provide recognition, verification, and visibility.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.